Volker Sandig

USPTO Granted Patents = 13 (Patent Applications = 7)

CIPO Patents = 3 (Patent Applications = 6)

EPO Patents = 5 (Patent Applications = 18)

Average Co-Inventor Count = 2.8

ph-index = 5

Forward Citations = 51(Granted Patents)

Company Filing History:

Max-planck-gesellschaft Zur Förderung Der Wissenschaften E. V.

Years Active: 1999-2024

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11999975 - Method for purifying an enveloped virus (2024-06-04),

2. 11104884 - Vaccinia virus vectors related to MVA with extensive genomic symmetries (2021-08-31),

3. 11060069 - Porcine cell line for virus production (2021-07-13),

4. 9765158 - Methods for preparation of fucose-linked site specific conjugates of proteins with toxins, adjuvants, detection labels and pharmacokinetic half life extenders (2017-09-19),

5. 9732325 - MVA virus and uses thereof (2017-08-15),

6. 9163089 - Enhancement of protein production yield mediated by a fast shuttling CDC42 GTPase (2015-10-20),

7. 8940534 - Immortalized avian cell lines for virus production (2015-01-27),

8. 8815540 - Productivity augmenting protein factor, novel cell lines and uses thereof (2014-08-26),

9. 8679839 - Cell line from rousettus as host cell for pathogen amplification (2014-03-25),

10. 8642292 - Process for producing molecules containing specialized glycan structures (2014-02-04),

11. 7132277 - Helper dependent vector system for gene therapy (2006-11-07),

12. 6025195 - Liver-specific adenovirus expression vector (2000-02-15),

13. 5895759 - Vector for gene transfer in liver cells (1999-04-20),

Title: Volker Sandig: Innovator in Viral Research

Introduction

Volker Sandig is a prominent inventor based in Berlin, Germany. He has made significant contributions to the field of virology, particularly in the purification and application of enveloped viruses. With a total of 13 patents to his name, Sandig's work has advanced the understanding and treatment of viral infections.

Latest Patents

Among his latest patents is a method for purifying an enveloped virus. This invention relates to a novel approach that enhances the efficiency of virus purification processes. Another significant patent involves vaccinia virus vectors related to Modified Vaccinia Ankara (MVA) with extensive genomic symmetries. This invention not only describes a new MVA-related virus but also outlines methods for culturing and producing this virus. Furthermore, it includes a pharmaceutical composition that incorporates the MVA-related virus, along with various acceptable excipients, diluents, and carriers. Additionally, the patent discusses the use of this MVA-related virus in vaccine development and its potential applications in medicine.

Career Highlights

Volker Sandig has worked with notable organizations such as Probiogen AG and the Max Planck Society for the Advancement of Science. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Some of his notable coworkers include Ingo Jordan and Hans Henning Von Horsten. Their collaborative efforts have further enriched the research landscape in virology.

Conclusion

Volker Sandig's innovative work in the field of virology has led to significant advancements in the purification and application of enveloped viruses. His contributions continue to impact the scientific community and pave the way for future research in viral therapies.

This text is generated by artificial intelligence and may not be accurate.